Financials data is unavailable for this security.
View more
Year on year China Shineway Pharmaceutical Group Ltd grew revenues 14.32% from 3.95bn to 4.52bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 34.14% net income growth from 722.77m to 969.51m.
| Gross margin | 75.21% |
|---|---|
| Net profit margin | 26.27% |
| Operating margin | 34.16% |
| Return on assets | 11.76% |
|---|---|
| Return on equity | 15.81% |
| Return on investment | 15.47% |
More ▼
Cash flow in CNYView more
In 2023, China Shineway Pharmaceutical Group Ltd increased its cash reserves by 17.16%, or 862.51m. The company earned 932.64m from its operations for a Cash Flow Margin of 20.65%. In addition the company used 49.54m on investing activities and also paid 26.74m in financing cash flows.
| Cash flow per share | 1.84 |
|---|---|
| Price/Cash flow per share | 4.67 |
| Book value per share | 9.76 |
|---|---|
| Tangible book value per share | 9.50 |
More ▼
Balance sheet in CNYView more
| Current ratio | 3.48 |
|---|---|
| Quick ratio | 3.14 |
| Total debt/total equity | 0.0479 |
|---|---|
| Total debt/total capital | 0.0457 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 26.57% and 34.14%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is above the industry average.
| Div yield(5 year avg) | 5.75% |
|---|---|
| Div growth rate (5 year) | 12.88% |
| Payout ratio (TTM) | 0.00% |
| EPS growth(5 years) | 15.72 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 25.07 |
More ▼
